Coronary Artery Disease
Conditions
Keywords
Coronary artery disease, hyperuricemia, coronary plaque volume, IVUS
Brief summary
The purpose of this study is to investigate the effects of febuxostat on coronary plaque volume in patients with chronic stable angina and hyperuricemia.
Detailed description
Patients with stable angina and hyperuricemia who undergo percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) are enrolled. Participants will be randomly assigned to one of the two treatment groups. Febuxostat group and A lifestyle modification group. At 8-12 months, routine follow up angiography and IVUS interrogation as well as endothelial function and several bio markers will be assessed.
Interventions
DRUGFebuxostat
The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
Sponsors
Yokohama City University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients 20 years of age or older at enrollment who are able to visit 2. Patients with chronic stable angina who have severe coronary stenosis wich require PCI. 3. Patients who have at least one coronary plaque (≧ 500μm in thickness or % plaque of 20% or more) at the non-culprit vessels. 4. Patients with hyperuricemia, who have a serum uric acid level \>7.0mg/dL within 2 months prior to enrollement. 5. Patients who personally given written informed consent to participate in this study.
Exclusion criteria
1. Patients who had undergone previous PCI for the lesion under investigation. 2. Patients with gouty tophus, or patients with subjective symptoms of gouty arthritis within 1 year prior to enrollment. 3. Patients with a previous history of hypersensitivity to febuxostat or allopurinol. 4. Patients with serious kidney disease, Acute kidney disease, nephrotic syndrome, dialysis patients, kidney transplant patients, eGFR \< 30 mL/min/1.73m2, etc. 5. Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 2 or more times the upper limit of normal. 6. Patients on any of the following medications at enrollment Mercaptopurine hydrate, azathioprine, vidarabine, or didanosine. 7. Patients who receive any of the following medications for the treatment of hyperuricemia within 1 month prior to enrollment Allopurinol, benzbromarone, probenecid, bucolome, topiroxostat, or febuxostat. 8. Patients otherwise judged by the principal or sub-investigator to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percent changes in coronary plaque volume obtained by IVUS from baseline to follow up | 8-12 months |
| The percent changes in integrated backscatter signal obtained by integrated backscatter IVUS from baseline to follow up | 8-12 |
Secondary
| Measure | Time frame |
|---|---|
| changes in plaque characteristics assessed by IVUS from baseline to follow up | 8-12 months |
| changes in serum uremic values and inflammatory markers from baseline to follow up | 8-12 months |
| absolute changes of coronary plaque volume by IVUS from baseline to follow up | 8-12 months |
| nominal changes in plaque burden assessed by IVUS from baseline to follow up | 8-12 months |
| nominal changes in plaque burden adjusting for analyzed length assessed by IVUS from baseline to follow up | 8-12 months |
| prognosis(death, ACS, restenosis) | 8-12 months |
| absolute and percent changes in minimal lumen diameter and percent stenosis by QCA from baseline to follow up | 8-12 months |
Countries
Japan
Outcome results
None listed